Journal article

The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions

Patricia T Illing, Anthony W Purcell, James McCluskey

IMMUNOGENETICS | SPRINGER | Published : 2017

Abstract

Genetic polymorphism in the genes encoding the human leukocyte antigen (HLA) molecules enables presentation of a wide range peptide ligands thus maximising immune surveillance of pathogens. A consequence of the diversification of the HLA Ag-binding pocket is the enhanced opportunity for off-target binding of small drugs by HLA molecules, with subsequent immune reactivity. These potential off-target interactions are 'set up' to generate T cell-mediated adverse drug reactions even though the precise mechanisms of most HLA-drug interactions are still poorly understood. The association between abacavir hypersensitivity syndrome and HLA-B*57:01 is one exception that has been resolved at a molecul..

View full abstract

University of Melbourne Researchers

Grants

Awarded by Australian National Health and Medical Research Council (NHMRC)


Awarded by NHMRC Senior Research Fellowship


Awarded by NHMRC


Funding Acknowledgements

PTI is supported by an Australian National Health and Medical Research Council (NHMRC) Early Career Fellowship (1072159). AWP is supported by a NHMRC Senior Research Fellowship (1044215) and a NHMRC project grant (1122099). JMc was supported by a NHMRC Project Grant (1120467) and Program Grant (1113293). Thank you to Julian Vivian and Jamie Rossjohn for assistance with structural figures.